Dimerix Limited announced the appointment of a medical advisory board (MAB) to help guide the company's DMX-200 clinical program. The medical advisory board will provide clinical and strategic input into the company's lead program, DMX-200 in Chronic Kidney Disease and will provide guidance to the company as it shapes and progresses its DMX-200 programs. The MAB will have no formal governance role. Associate Professor David Packham (MD, MB, BS (Hons), FRCP, FRACP) will lead the MAB in the position of Chair, where he will be joined by: Professor David Power, MD, MB, BS, PhD, MRCP(UK), FRACP; Daniel Cattran, MD, FRCP (C); Alessia Fornoni, MD, PhD, FASN; Jonathan Hogan, MD. Assoc Prof Packham is the director of the Melbourne Renal Research Group. In this capacity, he has been involved in the development of protocols for numerous clinical trials and has held the position of national or regional co-ordinator for many trials. Professor Power is Director of Nephrology, Austin Health, Heidelberg, Victoria and a Professorial Fellow, Department of Medicine, University of Melbourne. David has always worked as a clinician, and is actively involved in the clinical management of patients with kidney disease, mainly in the Department of Nephrology at Austin Health. Dr. Cattran is currently a Professor of Medicine at the University of Toronto and a Senior Scientist at the Toronto General Research Institute. His administrative roles have included Chairman of the Royal College of Canada specialty program in nephrology, and director of the PGE program in nephrology at the University of Toronto. He was co-chairman of the KDIGO working group that developed the published guideline for glomerulonephritis management. Dr. Fornoni is tenured Professor of Medicine and Molecular and Cellular Pharmacology at the University of Miami Miller School of Medicine. She is the Chief of the Division of Nephrology and Hypertension and serves as and Director and Chair of the Peggy and Harold Katz Drug Discovery Center. She is also the Associate Director of the MD PhD program. Dr. Fornoni gained experience in drug development as Global Head of Discovery in Cardiovascular and Metabolism at Hoffman- La Roche in Basel. She is currently the Vice-President and Chief Scientific Officer of L&F Health LLC. Dr. Hogan is Clinical Director of the Penn Glomerular Disease Center, and Assistant Professor of Medicine, Division of Nephrology, at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, PA, USA. His expertise includes glomerular diseases (including vasculitis, lupus nephritis, nephrotic syndrome, and FSGS), onconephrology (kidney disease in patients with cancer), and paraprotein- associated kidney diseases.